PharmaTimes -
November 2020

Our cover feature this month (p19) highlights pharma’s laudable ability to continually innovate in the logistics landscape to secure a continuous supply of medicine, having to meet ever-changing demands and challenges such as fluctuating market dynamics, new regulation, climate change, the emergence of highly specialist therapies and, new for 2020, pandemics. As John Pinching notes, it’s an area of pharma often unheralded and yet constantly ‘looking forward, setting the pace and reaching further’.

Also on the theme of COVID-19, on page 40 Accenture’s Brad Michel describes how pharma companies have improved how they engage with healthcare providers during the pandemic. He says there’s ‘a unique opportunity’ for pharma to increase its relevance to healthcare professionals and patients, ‘with lasting impact post-pandemic’. On page 32, Chris Sigley outlines findings of a survey of life sciences professionals, commissioned by Arkivum in collaboration with Phlexglobal and the Ethical Medicines Industry Group (EMIG), into the conduct of clinical trials and management of trial data; 70% of the 200+ respondents said COVID-19 has triggered a change in the way clinical trials will be conducted, again highlighting the wide-ranging impact of the pandemic.

Elsewhere, OVID Health’s Rachel Gonzaga highlights the key lessons from the Patient Partnership Conference (p36), while on page 24 we celebrate the winners of the 2020 PharmaTimes Clinical Researcher of the Year – The America’s competition. Congratulations to all finalists and winners!

November 2020 - magazine highlights

Thumbnail image for Star tracking across the pharmaverse

Star tracking across the pharmaverse

While the COVID-19 menace has wreaked havoc across global industries, pharma’s commitment to logistical zeal has provided a supersonic slipstream to optimal performance, not to mention salvation for millions of patients

Thumbnail image for Maintaining cross-border medicines supply

Maintaining cross-border medicines supply

Updated guidelines from the European Medicines Agency for pharmaceuticals marketing authorisation holders offer new clarity on what they must do to maintain continuity of supply of UK-registered products in Europe once the Brexit transition period ends.

Thumbnail image for Artificial inventors

Artificial inventors

The question of artificial intelligence as an inventor – and what it means for drug discovery

Thumbnail image for Branching out

Branching out

Pharma companies have improved how they engage with healthcare providers during COVID-19, says Accenture’s Brad Michel

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download